September 30, 2010
Masur Auditorium on the NIH Campus
Bethesda, MD
Program Schedule
To view slides from a presenter click the icon next to the presentation title.
Thursday, September 30, 2010 |
|
8:00 am - 8:05 am | Welcome and Introduction Francesco Marincola, MD - National Institutes of Health (CC, DTM) |
8:05 am - 8:20 am | ![]() Bernard A. Fox, PhD - Earle A. Chiles Research Institute |
8:20 am - 8:30 am | Priorities in Biomarkers Development in Immunotherapy Samir N. Khleif, MD – Vaccine Branch NCI, NIH |
8:30 am - 9:45 am | Session 1: Immunologic Monitoring: Standardization and Validation of Assays Chair: Lisa H. Butterfield, PhD - University of Pittsburgh ![]() Lisa H. Butterfield, PhD – University of Pittsburgh ![]() Paul V. Lehmann, MD, PhD – Cellular Technology Limited ![]() Cedrik M. Britten, MD – Association for Cancer Immunotherapy (CIMT) Panel Discussion Panelists: Session 1 Speakers: Sylvia Janetzki, MD - ZellNet Consulting, Inc. and Cancer Immunotherapy Consortium; and Michael Kalos, PhD - University of Pennsylvania |
10:00 am - 12:00 pm | Session 2: Correlation of Immunity to Clinical Response and Potency Assays Chair: Mary L. (Nora) Disis, MD - University of Washington ![]() Raj K. Puri, MD, PhD – U.S. Food and Drug Administration (CBER) ![]() Mary L. (Nora) Disis, MD – University of Washington ![]() David Stroncek, MD – National Institutes of Health ![]() Mark W. Frohlich, MD – Dendreon Corporation Panel Discussion Panelists: Session 2 Speakers; Leif Håkansson, MD, PhD - Biotherapy Development Association; and Nicholas P. Restifo, MD - National Cancer Institute |
1:15 pm - 3:00 pm | Session 3: Novel Methodologies for Assessing the Immune Landscape: Clinical Utility of Novel Technologies Co-Chairs: Francesco Marincola, MD - National Institutes of Health (CC, DTM) Peter P. Lee, MD - Stanford University ![]() Thomas R. O’Brien, MD – National Cancer Institute, Division of Cancer Epidemiology and Genetics A Critical Concentration of Cytolytically Active, Tumor Antigen-Specific CD8+T-Cells Is Required to Control Growth of Cognate Antigen-Expressing Tumor Cells In Vitro and In Vivo Samuel C. Silverstein, MD – Columbia University Immune Biomarkers: A Novel Paradigm for Cancer Jérôme Galon, PhD – INSERM, Integrative Cancer Immunology Laboratory, Cordeliers Research Center ![]() Peter P. Lee, MD – Stanford University Panel Discussion Panelists: Session 3 Speakers; Co-Chairs and Aniruddha (Raja) Choudhury, PhD Nordic Center for Development of Antitumor Vaccines, NCV-network |
3:15 pm - 4:45 pm | Session 4: Recommendations on Incorporation of Biomarkers into the Clinical Arena Chair: John M. Kirkwood, MD - University of Pittsburgh Cancer Institute ![]() Diane Longo, PhD – Nodality Inc. ![]() Daniel Normolle, PhD – University of Pittsburgh Cancer Institute ![]() Holden T. Maecker, PhD – Stanford University Medical Center ![]() Howard L. Kaufman, MD, FACS – Rush University Medical Center |
4:45 pm - 5:00 pm | Summary and Conclusions of the Biomarkers Symposium Lisa H. Butterfield, PhD - University of Pittsburgh |
Friday, October 1 |
|
8:00 am - 5:00 pm | Workshop on Monoclonal Antibodies in Cancer For more information, please click here. |
8:00 am - 5:00 pm | Primer on Tumor Immunology and Biological Therapy of Cancer For more information, please click here. |
Saturday, October 2 - Monday, October 4 |
|
iSBTc 25th Annual Meeting For more information, please click here. |
All presentations are licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.